Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, North Carolina, 27710.
Mol Carcinog. 2013 Dec;52(12):959-69. doi: 10.1002/mc.21936. Epub 2012 Jun 12.
Both EGFR and HER2 are important mediators of tumorigenesis and tumor progression. Despite their best-characterized roles as plasma membrane-bound receptors, both receptors undergo nuclear translocation though the impact of this process remains unclear. In this study, we provide evidence showing that EGFR upregulates expression of signal transducer and activator of transcription 1 (STAT1), a transcription factor responding to inflammatory signals and regulating genes involved in inflammatory response. EGFR regulation of STAT1 expression is primarily attributed to the nuclear activity of EGFR. The oncogenic transcription factor STAT3 binds to the STAT1 promoter and synergizes with nuclear EGFR to significantly enhance STAT1 gene expression. Structural characterization of the human STAT1 gene promoter indicates the presence of four functional STAT3-binding sites in the promoter and their importance in STAT1 co-regulation by EGFR and STAT3. The constitutively activated EGFR variant, EGFRvIII, also cooperates with STAT3 to activate the STAT1 gene promoter through the identified STAT3-binding sites within the promoter. Using human breast cancer cell lines, we further found a positive association between levels of STAT1, EGFR, and p-STAT3. Furthermore, we found that STAT1 expression is transcriptionally upregulated by HER2 and heregulin stimulation in breast cancer cells, and the level is further augmented by activated STAT3. In summary, we report in this study that STAT1 expression is upregulated by nuclear EGFR, EGFRvIII and HER2, and that STAT3 synergizes with the three receptors to further enhance STAT1 expression. These novel findings establish a novel link between the mitogenic ErbB signaling pathway and the inflammatory pathway mediated by STAT1.
表皮生长因子受体(EGFR)和人表皮生长因子受体 2(HER2)都是肿瘤发生和肿瘤进展的重要介质。尽管它们作为质膜结合受体的作用已得到充分研究,但这两种受体都经历核转位,尽管这一过程的影响尚不清楚。在这项研究中,我们提供的证据表明,表皮生长因子受体(EGFR)上调信号转导子和转录激活子 1(STAT1)的表达,STAT1 是一种转录因子,对炎症信号作出反应,并调节参与炎症反应的基因。EGFR 对 STAT1 表达的调控主要归因于 EGFR 的核活性。致癌转录因子 STAT3 与 STAT1 启动子结合,并与核 EGFR 协同作用,显著增强 STAT1 基因表达。人 STAT1 基因启动子的结构特征表明,启动子中存在四个功能 STAT3 结合位点,它们在 EGFR 和 STAT3 共同调节 STAT1 基因表达中非常重要。组成性激活的 EGFR 变体 EGFRvIII 也通过启动子内鉴定的 STAT3 结合位点与 STAT3 合作激活 STAT1 基因启动子。使用人乳腺癌细胞系,我们还发现 STAT1、EGFR 和 p-STAT3 的水平之间存在正相关。此外,我们发现 HER2 和人表皮生长因子(heregulin)刺激可转录上调乳腺癌细胞中的 STAT1 表达,并且激活的 STAT3 进一步增强该水平。总之,我们在这项研究中报告称,STAT1 表达受核 EGFR、EGFRvIII 和 HER2 上调,STAT3 与这三种受体协同作用,进一步增强 STAT1 表达。这些新发现确立了丝裂原性 ErbB 信号通路与由 STAT1 介导的炎症通路之间的新联系。